Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft-versus-host disease by inhibiting T-cell migration to the gastrointestinal tract

Yukie Tsubokura | Hideaki Yoshimura | Atsushi Satake | Yutaro Nasa | Ryohei Tsuji | Tomoki Ito | Shosaku Nomura

First Department of Internal Medicine, Kansai Medical University, Hirakata City, Osaka, Japan

Correspondence
Atsushi Satake, First Department of Internal Medicine, Kansai Medical University, Hirakata City, Osaka 573-1010, Japan.
Email: satakeat@hirakata.kmu.ac.jp

Funding information
Japan Society for the Promotion of Science, Grant/Award Number: KAKENHI/19K17874

Abstract
Introduction: Allogeneic hematopoietic stem cell transplantation (aHSCT) is a curative treatment for hematopoietic malignancies. Graft-versus-host disease (GVHD) is a major complication of aHSCT. After transplantation, the balance of immune conditions, such as proinflammatory cytokine level and T-cell subset count, influences GVHD magnitude. Lenalidomide (LEN) is an immunomodulatory drug used for treating several hematological malignancies such as multiple myeloma, adult T-cell lymphoma/leukemia, and follicular lymphoma. However, the impact of LEN on immune responses after aHSCT has not been elucidated.

Methods: We analyzed the lymphocyte composition in naïve mice treated with LEN. Subsequently, we treated host mice with LEN, soon after aHSCT, and analyzed GVHD severity as well as the composition and characteristics of lymphocytes associated with GVHD.

Results: Using a mouse model, we demonstrated the beneficial effects of LEN for treating acute GVHD. Although natural killer cells were slightly increased by LEN, it did not significantly change T-cell proliferation and the balance of the T-cell subset in naïve mice. LEN did not modulate the suppressive function of regulatory T cells (Tregs). Unexpectedly, LEN prevented severe GVHD in a mouse acute GVHD model. Donor-derived lymphocytes were more numerous in host mice treated with LEN than in host mice treated with vehicle. Lymphocyte infiltration of the gastrointestinal tract in host mice treated with LEN was less severe compared to that in host mice treated with vehicle. The percentage of LPAM-1 (α4β7-integrin)-expressing Foxp3−CD4+ T cells was...
1 | INTRODUCTION

Allogeneic hematopoietic stem cell transplantation (aHSCT) is a curative therapy for various hematopoietic diseases, especially hematological malignancies. Allogeneic responses mediated by donor-derived T cells cause the graft-versus-leukemia effect, which is an advantage of aHSCT; however, excessive immune responses may cause severe graft-versus-host disease (GVHD). Acute GVHD (aGVHD) is a major complication of aHSCT, causing high morbidity and mortality.\(^1\) Corticosteroids are used as a standard treatment for aGVHD. The response rate of corticosteroid therapy is approximately 50%–60%.\(^2,3\) and patients who do not respond to corticosteroid therapy have higher mortality than patients who have steroid-responsive GVHD.\(^4,5\)

Recipients who undergo aHSCT for high-risk diseases are frequently treated with specific antileukemic agents before and after aHSCT because of a substantial need to prevent or treat disease recurrence. However, some of these drugs, such as tyrosine kinase inhibitors, monoclonal antibodies, and immunomodulatory drugs (IMiDs), may influence immune reactions after aHSCT. For instance, pretransplantation use of anti-CC chemokine receptor 4 monoclonal antibody is associated with an increased risk of steroid-resistant aGVHD and worsened clinical outcome in adult T-cell leukemia/lymphoma patients.\(^6\) Post-aHSCT maintenance with sorafenib, a multitargeted tyrosine kinase inhibitor, reduces the risk of relapse and death in patients with FMS-like tyrosine kinase 3-internal tandem duplication mutation-positive acute myeloid leukemia.\(^7,8\) Sorafenib may induce graft-versus-leukemia activity by inducing the production of interleukin-15 in leukemia cells.\(^9\) Therefore, it is important to understand the impact of these antileukemic agents on immune responses in aHSCT.

Lenalidomide (LEN) is a derivative of thalidomide, which is infamous for its teratogenicity following use as an antiemetic in pregnant women. LEN shows antitumor activity in some hematological malignancies.\(^10–13\) Currently, it is used in Japan for treating patients with multiple myeloma, myelodysplastic syndromes with chromosome 5q deletion, and relapsed/refractory adult T-cell leukemia/lymphoma. Thalidomide, LEN, and another thalidomide derivative—pomalidomide—are designated as IMiDs because these drugs can increase IL-2\(^{14–16}\) and interferon-\(\gamma\) (IFN-\(\gamma\)) production in T-cells,\(^17\) decrease proinflammatory cytokine production, and augment innate immunity by enhancing \(\gamma\delta\) T cell, natural killer (NK) cell, and NK T-cell activities.\(^18–21\) Regarding regulatory T cells (Tregs), the effect of LEN is controversial. Treg counts increased in patients treated with LEN and dexamethasone.\(^22\) LEN maintenance therapy for multiple myeloma patients increased the percentage of Tregs.\(^23\) By contrast, some reports showed that LEN may negatively affect the proliferation and suppressive function of Tregs.\(^24–26\) LEN could be used after aHSCT for patients with aggressive adult T-cell lymphoma/leukemia, relapsed/refractory peripheral T-cell lymphoma, and multiple myeloma; however, the effect of LEN on alloimmune reaction is unclear. In this study, we investigated the effects of LEN on T and NK cells in syngeneic and allogeneic settings, and its impact on aGVHD. We show that administration of LEN early after aHSCT contributes to protection against severe GVHD through the inhibition of T-cell migration to the gastrointestinal tract.

2 | MATERIALS AND METHODS

2.1 | Mice

Female C57BL/6 (B6) (H-2\(^b\)) and BALB/c (H-2\(^d\)) were purchased from Japan SLC. Ly5.1 congenic B6 mice (CD45.1\(^+\)) were purchased from Sankyo Labo Service. B6 (CD45.2\(^+\)) Foxp3 GFP knock-in (Foxp3.GFP KI) mice were purchased from Jackson Laboratories. CD45.1\(^+\)
Foxp3.GFP KI mice on a B6 background were created by crossing Ly5.1.B6 mice with Foxp3.GFP KI mice. The mice were 8–16 weeks old at the time of sacrifice. All mice were housed in specific pathogen-free conditions and treated in strict compliance with Animal Facility regulations of the Kansai Medical University. For euthanasia and terminal experiments, they were euthanized either with a CO2 inhalant or pentobarbital overdose followed by cervical dislocation. Efforts were made to minimize the suffering of study animals throughout all experiments. All research staff were educated about animal care by the Animal Care Committee of the Kansai Medical University at the beginning of the study. All animal studies were approved by the Animal Care Committee of the Kansai Medical University (approval number. 19-101).

2.2 Antibodies and reagents

Anti-CD4 (RM4-5), anti-CD45.1 (A20), anti-CD45.2 (104), anti-CD8α (53-6.7), anti-T-cell receptor-β (TCRβ) (H57-597), anti-CD44 (IM7), anti-CD62L (MEL-14), anti-NK1.1 (PK136), anti-granzyme B (GB11), anti-IFN-γ (XMG1.2), anti-IL-17A (TC11-18H10.1), anti-IL-10 (JES5-16E3), anti-IL-20 (OX40) (OX-86), anti-GITR (DTA-1), anti-CD122 (SH4), anti-ICOS (C398.4A), and anti-LPAM-1 (DATK32) antibodies for flow cytometry were purchased from BioLegend. Fc block (2.4G2) and anti-CD11c (FJK-16s) was obtained from eBioscience. Fc block (2.4G2) and anti-CD11c antibody (UC10-4F10-11) were obtained from Tonbo Bioscience, whereas anti-IL-2 antibody (JES6-5H4) was obtained from Miltenyi Biotec. Aqua fluorescent LIVE/DEAD™ stain and carboxyfluorescein succinimidyl ester (CFSE) was obtained from Invitrogen. Cells were stained using LIVE/DEAD™ stain before surface antibody staining or intracellular staining for IFN-γ, IL-17, IL-2, FoxP3, or CD11c. LEN was obtained from FUJIFILM Wako Pure Chemical Corporation. A stock solution of LEN was prepared in dimethyl sulfoxide, stored at -80°C, and diluted with sterile phosphate-buffered saline (PBS) immediately before the experiments were conducted.

2.3 Flow cytometry, cell sorting, and data analysis

Flow cytometry was performed using FACSCanto (BD Biosciences). For cell sorting, T cells were purified using the Pan T-cell Isolation Kit (Miltenyi Biotec) before cell surface staining with an antibody against CD4 and CD8. FoxP3+ and Foxp3−CD4+ T cells were sorted by GFP fluorescence using the Foxp3.GFP KI mouse. Fluorescence-activated cell sorting (FACS) was performed using the FACSaria cell sorter (BD Biosciences) at the Central Research Laboratory of Kansai Medical University. FACS-sorted populations were of >95% purity. Data were analyzed using FlowJo software (version 8.8.7; TreeStar). Dead cells were excluded from the analysis using LIVE/DEAD™ fixable aqua dead cell staining. Statistical analysis was performed using Student's t-test or analysis of variance using Prism (GraphPad) as appropriate.

2.4 In vitro T-cell proliferation assays

For Tconv proliferation assays, FACS-sorted Foxp3.GFP−CD4+ T cells were labeled with CFSE. CFSE-labeled Tcons (5 × 10⁴ cells/well) and magnetic-activated cell sorting (MACS)-sorted CD11c+ dendritic cells (DCs; 1 × 10⁵ cells/well) were cocultured in the presence of anti-CD3 antibody (0.1 mg/ml) and granulocyte–macrophage colony-stimulating factor (GM-CSF) (10 ng/ml) with or without LEN at 37°C and analyzed using flow cytometry after 3 days. CD11c+ DCs were obtained from spleens of mice subcutaneously injected 14–21 days prior with FLT3L-expressing EL4 cells. For Treg proliferation assays, FACS-sorted Foxp3.GFP+CD4+ Tregs were labeled with CFSE. CFSE-labeled Tregs (1 × 10⁴ cells/well) and MACS-sorted DCs (1 × 10⁵ cells/well) were plated in 200 μl T-cell media (MEM-a with 10% fetal bovine serum, 1% penicillin/streptomycin, 10 mM HEPES, and 1 × 10⁻⁵ M 2-mercaptoethanol) with mouse GM-CSF (10 ng/ml; ATGen), human IL-2 (50 U/ml; PeproTech), and anti-CD3 (0.1 mg/ml; BD Biosciences) in 96-well flat-bottom plates. Cells were cultured with or without LEN at 37°C and analyzed using flow cytometry after 4 days.

2.5 In vitro inducible Tregs (iTreg) conversion assay

A total of 5 × 10⁴ FACS-sorted Tcons (Foxp3.GFP−CD4+) and CD8+ T cells (Foxp3.GFP−CD8+) from Foxp3.GFP-reporter mice were stimulated in 96-well culture plates with 5 × 10⁶ irradiated splenocytes with anti-CD3 (2 mg/ml), IL-2 (50 U/ml), and human tumor growth factor-β (TGFβ) (0.2 ng/ml for CD4+ and 1 ng/ml for CD8+ T-cell cultures). In some wells, LEN was added at different concentrations as indicated. After 5 days, the T cells were analyzed for Foxp3 expression using flow cytometry.
2.6 | In vivo LEN administration

LEN was dissolved at different concentrations in 400 μl PBS and stored at 4°C for the duration of the experiment. Vehicle (PBS) and LEN were injected intraperitoneally as indicated. Spleen tissue was collected after 1, 2, and 3 weeks of LEN injections (5 consecutive days/week) to evaluate the effect of LEN on T and NK cell counts using flow cytometry.

2.7 | Treg suppression assays

To determine the suppressive activity of CD4+ Tregs, GFP+ Tregs were sorted using FACS from the spleens of CD45.1+ Foxp3.GFP KI mice. CD4+GFP− Tconvs were sorted through FACS from CD45.2+Foxp3.GFP KI mice as effectors. Tconvs were CFSE labeled and cocultured with the sorted Tregs at various Tconv:Treg ratios in 200 μl of T-cell medium and stimulated with 5 × 10^6 irradiated feeder splenocytes and anti-CD3 (0.1 mg/ml) in the presence or absence of LEN in 96-well round-bottom tissue culture plates. CFSE dilution of Tconvs was analyzed 4 days after coculture, and the division index was calculated using FlowJo software.

2.8 | Induction and assessment of GVHD

BALB/c mice were administered a single dose of 800 cGy total body irradiation. Irradiated host mice were intravenously injected with 1.0 × 10^6 T cells enriched using MACS (Miltenyi Biotec) and 5.0 × 10^6 T-cell-depleted bone marrow (BM) cells from allogeneic donor (B6) or syngeneic donor mice. Host mice were treated with vehicle or LEN (2 or 50 mg/kg) for 14 days (0–13 days). After transplantation, mice were monitored every day for survival. Survival curves were plotted using the Kaplan–Meier method and compared using a log-rank test (*p < .05; GraphPad Prism 6.0). The degree of clinical GVHD was assessed 2–3 times per week until Day 38 using a scoring system that summarizes the changes in five clinical parameters: weight loss, posture, activity, fur texture, and skin integrity. Mice were humanely euthanized within 12 h of their body weight dropping to <30% of the initial body weight, or when moribund and visual signs of GVHD were present. For histopathological analysis, the small intestine, colon, and liver of recipients were removed and fixed immediately in 10% formalin, embedded in paraffin, sectioned, mounted on slides, and stained with hematoxylin and eosin.

2.9 | Phenotypic and functional analysis of T cells during GVHD

Irradiated BALB/c mice were injected intravenously with 5 × 10^6 T-cell-depleted BM cells and 1.0 × 10^6 CD4+ T cells from B6 mice (CD45.1+). Fourteen days after transplantation, donor cells from the spleen and mesenteric lymph nodes were phenotypically analyzed using flow cytometry. To measure cytokine production, isolated lymphocytes of the spleen and mesenteric lymph nodes were cultured in the presence of phorbol myristate acetate (PMA; 50 ng/ml), ionomycin (1 mg/ml), and brefeldin A (10 mM) for 5.0 and 2.5 h before antibody staining, respectively.

2.10 | Cytokine analysis

Peripheral blood was collected from host mice 14 days after aHSCT. Cytokine concentrations of serum were analyzed using the BD Cytometric Bead Array system (mouse Th1/Th2/Th17 cytokine kit; BD Biosciences), according to the protocol described by the manufacturer.

2.11 | Cell isolation from the small intestine

The whole small intestine obtained from host mice 14 days after aHSCT was processed using a gentleMACS Dissociator (Miltenyi Biotec) and mouse lamina propria dissociation kit (Miltenyi Biotec), according to the manufacturer’s protocol.

2.12 | Migration assay of T cells

T cells were magnetically sorted from host mice transplanted from an allogeneic donor. A total of 10^6 T cells were suspended in 200 μl RPMI and placed in the upper compartment of a 24-well sterile Transwell device (Corning Life Sciences) that was separated from the bottom well by a 5-μm filter. The filters of the upper chamber were coated with recombinant mucosal vascular addressin cell adhesion molecule-1 (MAdCAM-1; 10 μg/ml; R&D Systems) before incubation. To promote migration, recombinant mouse CCL25 (BioLege) was added to the bottom well (100ng/ml, 1 ml final volume), and incubated at 37°C. After 6 h, the migrated T cells were counted by flow cytometry analysis within the bottom compartment and calculated as the number of T cells that migrated in response to the recombinant mouse MAdCAM-1.
2.13 | Statistical analysis

Prism (GraphPad) was used for statistical analysis. Data from independent repeats of experiments were graphed as individual data points with a mean ± SD for each group. The data were graphed and analyzed for statistical significance. The statistical test used to calculate each p value is indicated in the figure legends. p < .05 were considered significant.

3 | RESULTS

3.1 | LEN did not interfere with T-cell proliferation and homeostasis

To investigate the effect of LEN on T cell proliferation, we performed a T-cell proliferation assay in the presence and absence of LEN. In this analysis, we examined the effect of LEN on Tconv and Treg proliferation in the presence of TCR stimulation (Figure 1A). Tconv proliferation was not inhibited at all by LEN (Figure 1B). Similarly, Treg proliferation was not inhibited by LEN, although inconsiderable inhibition of Treg proliferation was observed at medium and high LEN concentrations (Figure 1C). Next, we examined the effect of LEN on the conversion of iTregs. LEN did not affect iTreg formation stimulated by anti-CD3 in the presence of TGFβ and IL-2 (Figure 1D).

Subsequently, to evaluate the effect of LEN in vivo, we injected either vehicle or LEN into wild-type B6 mice. LEN administration marginally increased T-cell numbers in the spleen, whereas CD4+ T-cell counts seemed to be slightly increased compared to CD8+ T cell counts (Figure 2A–D). In particular, the percentage of central memory T cells (Tcm; CD4+CD44+CD62+) was augmented by LEN administration after 3 weeks (Figure 2E, F). Consistent with the results of in vitro Treg proliferation assay, the percentage and number of Treg in mice injected with LEN were comparable with those injected with the vehicle (Figure 2G–I). Alternatively, NK cell counts were higher in LEN-injected mice than in vehicle-injected mice, and granzyme B expression was upregulated after 3 weeks of LEN injection (Figure 2K–N).

3.2 | LEN did not regulate the suppressive function of Tregs

We analyzed Tregs for the expression of surface markers commonly associated with Treg function. Tregs from LEN- and vehicle-treated mice expressed comparable

**FIGURE 1** T-cell proliferation is maintained in the presence of lenalidomide in vitro. (A) Experimental scheme. CFSE-labeled Tconv and Treg were cultured with syngeneic DCs. (B) Representative histograms showing Tconv and Treg CFSE dilution with several concentrations of LEN. (C) The division index of T cells cultured with LEN was normalized to that of the control, and compiled data from four independent experiments are shown. (D) FACS-sorted CD4+ Fosp3.GFP+ Tconvs were stimulated with plate-bound anti-CD3/anti-CD28 and soluble TGFβ and IL-2 with or without LEN. After 4 days, the cells were harvested and analyzed using flow cytometry. Representative plots (left panel) are shown, and compiled data from three independent experiments are shown as the mean ± SD (right panel). CFSE, carboxyfluorescein succinimidy ester; FACS, fluorescence-activated cell sorting; IL-2, interleukin-2; LEN, lenalidomide; TGFβ, tumor growth factor-β; Treg, regulatory T cell.
levels of the high-affinity IL-2 receptor (CD122 and CD25) and other coreceptors (OX40, GITR, and CTLA-4) (Figure 2J). Next, we tested the suppressive function of Tregs in the presence and absence of LEN (Figure 3A). Tconv proliferation was equally suppressed by Tregs with or without LEN (Figure 3B, C), suggesting that LEN did not change the suppressive function of Tregs.

### 3.3 High-dose LEN administration prevented GVHD mortality

LEN did not significantly affect Tregs and Tconvs in vitro and in a steady state, suggesting that LEN did not change alloimmune responses. To test the effect of LEN on aGVHD, we used a major histocompatibility complex (MHC)-mismatched aGVHD mouse model. Host mice were treated with vehicle or LEN (2 and 50 mg/kg) for 14 days starting on the day of transplantation, and survival and body weight were monitored. GVHD-induced mortality in host mice treated with a low dose (2 mg/kg) of LEN was slightly, but not significantly, enhanced compared with that of host mice treated with vehicle (Figure 4A). GVHD-induced mortality in host mice treated with a high dose (50 mg/kg) of LEN was significantly ameliorated compared with that of host mice treated with vehicle (Figure 4A). Body weight loss and severity of GVHD score of both low- and high-dose LEN-treated host mice transplanted from an allogeneic donor was marginally mild early after transplantation.

---

**Figure 2** Analysis of T-cell subset and NK cells in mice injected with or without lenalidomide. B6 mice were injected intraperitoneally with vehicle (PBS) or LEN (50 mg/kg) for 1–3 weeks, and designated cell subsets in the spleen were analyzed using flow cytometry after LEN injection. (A, E, G, K) Representative FACS plots of two independent experiments. (B) CD4+/CD8+ T-cell ratio and (C) the absolute number of CD4+ and (D) CD8+ T cells. (F) The percentage of naïve (CD44−CD62L+CD4+; left), central memory (CD44+CD62L−; middle), and effector (CD44+CD62L−) T cells (right). (H) The percentage and (I) absolute number of Tregs. Tregs were analyzed for expression of CD25, GITR, Helios, OX40, CD122, CTLA4, and ICOS. (J) Representative histograms. The shaded and open histograms represent Tregs isolated from B6 mice treated with PBS and LEN, respectively. (L) The percentage and (M) absolute number of NK cells. (N) A representative histogram of granzyme B (left) and the percentage of NK cells expressing granzyme B (right). The shaded and open histograms represent NK cells isolated from B6 mice treated with LEN and PBS for 3 weeks, respectively (left). Data are presented as the mean ± SD of n = 6 mice/group from two independent experiments. LEN, lenalidomide; NK, natural killer; PBS, phosphate-buffered saline. *p < .05 and **p < .01, calculated using the two-tailed Student’s t-test.
compared to that of vehicle-treated mice (Figure 4B, C). Consistent with these clinical findings, the protective effect of a high dose of LEN, such as cellular infiltration and tissue damage, was demonstrated by histopathological analysis of the small intestine and colon (Figure 4D). Alternatively, apparent differences in tissue damage and T-cell infiltration in the liver were not observed between host mice treated with vehicle and LEN. These results suggested that high-dose, and not low-dose, LEN treatment was beneficial for preventing gastrointestinal aGVHD.

3.4 LEN preserved donor-derived lymphocytes in the spleen after aHSCT

Next, to evaluate the effect of LEN on T and NK cells after aHSCT, we examined the number and subset of T cells in host mice on Day 14 after transplantation. Donor T-cell chimerism in host mice treated with LEN was similar to host mice treated with vehicle (<1% recipient cells) (Figure 5A). Regardless of treatment, CD4+ and CD8+ T-cell ratio was almost equal in all host mice (Figure 5B). Both the absolute number of CD4+ and CD8+ T cells were significantly increased in the spleen after transplantation in host mice treated with a high dose of LEN compared to those in host mice treated with vehicle (PBS vs. high LEN; CD4, p < .0001; CD8, p < .01), whereas this was not observed in mice treated with a low dose of LEN (Figure 5C). The percentage of Tregs, including CD4+ and CD8+ Tregs in host mice treated with low and high doses of LEN, was comparable to that of host mice treated with vehicle (Figure 5D). The absolute number of CD4+ and CD8+ Tregs significantly increased in host mice treated with a high dose of LEN compared to those treated with vehicle (Figure 5E). The percentage of T cells expressing Ki-67 was comparable among host mice transplanted from an allogeneic donor regardless of the treatment (Figure 5F). Next, we analyzed the expression of surface markers commonly associated with Tregs in allogeneic host mice. Similar to Tregs isolated from vehicle-treated host mice, Tregs isolated from host mice treated with high dose LEN expressed components of high-affinity IL-2R (CD25 and CD122) and other coreceptors important for the function of Tregs, including OX40, GITR, and CTLA4 (Figure 5G). Additionally, the absolute number of NK cells in host mice treated with a high dose of LEN was higher than that of host mice treated with a vehicle, whereas the percentages of NK cells in host mice treated with low and
high doses of LEN were comparable with that of host mice treated with vehicle (Figure 5H, I). These results suggested that administering LEN increased T and NK cells in the spleen while maintaining the balance of the CD4/CD8 ratio and the percentage of NK cells in the allogeneic setting.

3.5 | Immune polarization of T cells during GVHD was not skewed by LEN

To gauge the effect of LEN on the production of several cytokines from donor-derived T cells during GVHD, we examined the percentage of T cells expressing IFN-γ, IL-17, IL-4, IL-13, IL-2, IL-10, and TNF-α in host mice treated with a high dose of LEN and host mice treated with vehicle, as these cytokines are important for aGVHD pathogenesis and Treg proliferation.28,29 Lymphocytes isolated from the spleen were harvested on Day 14 after transplantation and analyzed after stimulation with PMA/ionomycin. The frequencies of CD4+ T cells expressing these cytokines in host mice treated with LEN were comparable to those in mice treated with vehicle (Figure 6A, C, E). The frequencies of CD8+ T cells expressing these cytokines in host mice treated with a high dose of LEN were comparable to those of host mice treated with vehicle (Figure 6B, D, F). Serum cytokine levels of host mice treated with LEN were also similar to those of host mice treated with vehicle (Figure 6G).

3.6 | Frequencies of LPAM-1 integrin-positive cells were decreased by LEN

Next, we attempted to determine the mechanism by which high-dose LEN administration induced protection against GVHD. According to the histopathological
analysis, the severity of small intestine and colon GVHD was attenuated by a high dose of LEN (Figure 4C). Furthermore, T cells were preserved in the spleen in host mice treated with LEN. Thus, we examined whether LEN induces low LPAM-1 (α4β7-integrin) expression, a gut-homing molecule, on T cells after aHSCT. The percentage of LPAM-1-positive T cells was significantly lower in Tconv isolated from mice treated with LEN compared to that isolated from mice treated with vehicle (Figure 7A, B). The percentage of Treg-expressing LPAM-1 in host mice treated with LEN was comparable to that of mice treated with vehicle (Figure 7B). These results suggest that LEN is associated with Tconv migration inhibition to the gut and may contribute to aGVHD inhibition. Consistent with these results, the number of donor T cells infiltrated in the small intestine isolated from host mice treated with LEN tended to be smaller than that of host mice treated with vehicle (Figure 7C).

As shown in the migration assay evaluating T-cell migration upon exposure to MAdCAM-1, which is expressed by venules in the mucosa-associated lymphoid tissues and can direct the migration of T cells expressing integrin α4β7 into intestinal mucosa, the number of migrated T cells isolated from host mice treated with LEN was higher, but not significantly, than from host mice treated with vehicle (PBS vs. high LEN; CD4, p = .25; CD8, p = .29) (Figure 7D).
DISCUSSION

In this study, we examined the effect of LEN on T-cell immune responses in the presence and absence of alloantigen stimulation. LEN does not interfere with the T-cell proliferation, the development of iTregs, and the suppressive function of Tregs in the syngeneic and allogeneic settings. We demonstrated that LEN ameliorated aGVHD and was associated with T-cell migration inhibition to the gastrointestinal tract. LEN downregulated LPAM-1 expression after aHSCT. Murai et al. demonstrated that LPAM-1 expression is associated with homing to the gastrointestinal tract and is important in developing intestinal GVHD. Additionally, donor T cells imprinted with LPAM-1 perpetuate severe aGVHD. Selective anti-α4β7-integrin monoclonal antibody (vedolizumab) may have the potential to ameliorate steroid-resistant gastrointestinal aGVHD.

Consistent with these findings, the frequency of LPAM-1-expressing Tconvns was significantly lower in mice treated with a high dose of LEN than in control mice. Additionally, the absolute number of T cells in the spleen was high in host mice treated with LEN, indicating that LEN might preserve T cells in secondary lymphoid organs. Alternatively, we could not find a significant difference between the number of donor-derived T cells that infiltrated the small intestine of host mice treated with LEN and that in host mice treated with vehicle (PBS) or high dose of LEN on Days 0–13. On Day 14 after transplantation, spleen and mesenteric lymph node cells were stimulated in vitro. The expression of IFN-γ, IL-17, and IL-2 by CD4+ T cells (A, C, D) and CD8+ T cells (B, E, F) were analyzed using flow cytometry. (A, B) Representative FACS plots of four (spleen) independent experiments. The percentage of IL-2+ TNF-α+, IFN-γ+, IL-4+, IL-10+, IL-13+, and IL-17+ CD4+ T cells in the spleen (C) and mesenteric lymph node (D). The percentage of TNF-α+, IFN-γ+, and IL-17+ CD8+ T cells in the spleen (E) and mesenteric lymph node (F). Compiled data four independent experiments are represented as the mean ± SD of n = 4 (syngeneic), 13 (LEN), and 17 (PBS). Compiled data from two independent experiments are shown as the mean ± SD of n = 4 (syngeneic), 6 (PBS), and 8 (LEN) mice/group. (G) Cytokine concentrations of serum obtained 14 days after aHSCT were analyzed. The levels of IL-2, TNF-α, IFN-γ, IL-4, IL-10, IL-6, and IL-17. Compiled data from four independent experiments are shown as the mean ± SD of n = 8 (syngeneic), 17 (PBS), and 13 (LEN) mice/group. Statistical analysis was calculated by two-tailed Student's t-test. aHSCT, allogeneic hematopoietic stem cell transplantation; IL, interleukin; IFN, interferon; LEN, lenalidomide; NK, natural killer; PBS, phosphate-buffered saline; TNF, tumor necrosis factor.

FIGURE 6 Administration of lenalidomide does not alter the percentage of T cells expressing cytokines after transplantation. T cells and T-cell-depleted BM cells from B6 or syngeneic BALB/c mice were injected into lethally irradiated BALB/c mice and subsequently treated with vehicle (PBS) or high dose of LEN on Days 0–13. On Day 14 after transplantation, spleen and mesenteric lymph node cells were stimulated in vitro. The expression of IFN-γ, IL-17, and IL-2 by CD4+ T cells (A, C, D) and CD8+ T cells (B, E, F) were analyzed using flow cytometry. (A, B) Representative FACS plots of four (spleen) independent experiments. The percentage of IL-2+, TNF-α+, IFN-γ+, IL-4+, IL-10+, IL-13+, and IL-17+ CD4+ T cells in the spleen (C) and mesenteric lymph node (D). The percentage of TNF-α+, IFN-γ+, and IL-17+ CD8+ T cells in the spleen (E) and mesenteric lymph node (F). Compiled data four independent experiments are represented as the mean ± SD of n = 4 (syngeneic), 13 (LEN), and 17 (PBS). Compiled data from two independent experiments are shown as the mean ± SD of n = 4 (syngeneic), 6 (PBS), and 8 (LEN) mice/group. (G) Cytokine concentrations of serum obtained 14 days after aHSCT were analyzed. The levels of IL-2, TNF-α, IFN-γ, IL-4, IL-10, IL-6, and IL-17. Compiled data from four independent experiments are shown as the mean ± SD of n = 8 (syngeneic), 17 (PBS), and 13 (LEN) mice/group. Statistical analysis was calculated by two-tailed Student's t-test. aHSCT, allogeneic hematopoietic stem cell transplantation; IL, interleukin; IFN, interferon; LEN, lenalidomide; NK, natural killer; PBS, phosphate-buffered saline; TNF, tumor necrosis factor.
with vehicle. This may be because LPAM-1+ T cells could migrate to other gastrointestinal tracts, as well as the small intestine. Although the precise mechanism modulated by LEN to reduce LPAM-1 expression remains unclear, we believe that the reduced LPAM-1 expression by high-dose LEN treatment mainly contributes to GVHD protection because gut GVHD is the main cause of mortality in the mouse model employed by us.

DCs are capable of inducing T-helper type 1 (Th1) and Th2 responses. Previous reports showed that IMiDs have immunomodulatory effects on DCs. Recently, our colleagues have reported that IMiDs enhance DC-mediated Th2 cell responses through upregulated STAT6 and IRF4 expression. TSLP-stimulated myeloid DCs enhanced the production of Th2 cytokines due to IMiDs. These modulations of DC-mediated response may contribute to the amelioration of aGVHD.

Treg is a crucial T-cell subset that maintains immune tolerance. Tregs suppress excessive autoimmune responses induced by self-MHC-reactive T cells. In addition to limiting T-cell responses against self MHC/peptide complexes and to pathogens, Tregs suppress allogeneic T-cell responses observed in graft rejection and GVHD. The intensity of the alloimmune reaction depends on the balance between Tconvs and Tregs. Thus, the collapse of this balance usually leads to an excessive alloimmune reaction. Thalidomide, LEN, and pomalidomide increase IL-2 and IFN-γ production in T-lymphocytes. IL-2 is a crucial cytokine for Tregs because the maintenance of the Treg population is achieved by a combination of survival and homeostatic proliferation attained by signaling through the cytokine receptor for IL-2 and TCR. Moreover, IL-2 is vital and irreplaceable for the development and function of Tregs. In this context, IMiDs are likely to increase Tregs because Tconvs serve as the main source of IL-2; however, in this study, we did not observe augmentation of Treg proliferation and function in addition to LEN.

Balance among Th1, Th2, Th17, and Tregs is an important determinant of the severity, manifestation, and tissue distribution of GVHD. LeBlanc et al. reported that IMiDs promote T-cell activation by augmenting CD28
tyrosine phosphorylation on T cells and subsequent nuclear factor-xB activation, a known downstream target of CD28 signaling. The authors showed that IMiDs promote IFN-γ secretion of T cells triggered by EBV and influenza. In addition, LEN elevated the concentration of IFN-γ and IL-6 in multiple myeloma patients. Therefore, it was expected that LEN might skew the polarization of T-cell immune response after aHSCT; however, the percentage of Th1 and Th2 cells was not changed by administering LEN. Th2 cells (IL4+ and IL13+) marginally increased in host mice treated with LEN.

IMiDs induce expansion and qualitative activation of NK cells and exert an antitumor effect. These effects of IMiDs are induced by triggering IL-2 production by T cells. The effect of LEN on patients who received aHSCT is still unknown. Lioznov et al. reported that administering LEN after aHSCT for relapsed multiple myeloma induces an increase of activated NK (NKp44+) cells and T (HLA-DR+) cells and shows clinical responses. Conversely, Dauguet et al. reported that LEN downregulates IFN-γ production and cytotoxicity receptor NKp46 expression. Although the absolute number of NK cells was considerably low because we used purified donor T cells as effector cells for GVHD induction, NK cells expanded due to high-dose LEN administration in the present study. LEN may contribute to the improvement of transplantation outcomes because NK cells prevent disease relapse, infection, and GVHD.

Some clinical studies with a few patients suggested that administering LEN after aHSCT may induce GVHD. Kneppers et al. reported that the LEN maintenance after aHSCT with nonmyeloablative conditioning was not feasible because 14 of 30 patients had to stop LEN due to the development of GVHD. Sockel et al. reported that LEN maintenance after aHSCT induced GVHD in patients with myelodysplastic syndrome, in line with data from multiple myeloma patients. In contrast to these results, LEN did not exacerbate GVHD in the present study. Unexpectedly, high-dose LEN administration significantly mitigated aGVHD. The immunomodulation by IMiDs might have different effects during different posttransplantation phases. LEN was used from the day of transplantation and discontinued 14 days after transplantation in our study, whereas it was initiated after engraftment and continued until disease progression or the emergence of intolerable adverse events in a clinical setting. In addition to the species differences in humans and rodents, this disparity may account for the differential effect of GVHD. Cereblon was identified as the primary target of thalidomide, and cereblon knockout on myeloma cell lines leads to LEN and pomalidomide resistance. Cereblon is ubiquitously expressed and forms a complex with three other proteins (CUL4, DDB1, and Roc1) to produce the cullin-4 RING E3 ligase complex, which has E3 ubiquitin ligase activity. Ikaros (IKZF1) and Aiolos (IKZF3) were key cereblon-interacting proteins. Cereblon has an enhanced affinity for IKZF1 and IKZF3, with subsequent ubiquitination and degradation of these proteins after binding of an IMiD to cereblon. This subsequently leads to changes in gene transcription including decreased expression of IRF4 and increased expression of IL-2. Although precise mechanisms explaining the discrepancy between the present study and previously reported data are not clear, the results of the present study may provide a clue for using a novel immunotherapy method that targets cereblon for GVHD.

This study has a few limitations. It is unknown whether high-dose LEN treatment for preventing GVHD is tolerable for patients directly after aHSCT. Next, the effect of LEN in humans may be different from that in rodents. The accurate cause of teratogenicity of thalidomide in humans is not elucidated yet, whereas rodents do not show teratogenicity at all. Although cereblon in humans and rodents is similar, four amino acids of the thalidomide-binding domain in mice are different from those in humans, and they cause interspecies specificity in antiproliferative effects against myeloma cells.

In conclusion, we have demonstrated that LEN does not affect the proliferation and function of Treg and that it slightly promotes the proliferation of Tcm and NK cells in a steady state. LEN decreased gastrointestinal damage associated with the decrease of LPAM-1 expression on T cells and mitigates aGVHD by storing donor-derived T cells in the spleen. Although further investigations are necessary, cereblon, a LEN target, may be a potential therapeutic target for preventing gastrointestinal GVHD.

AUTHOR CONTRIBUTIONS
Yukie Tsubokura, Hideaki Yoshimura, Yutaro Nasa, and Ryohei Tsuji performed the experiments. Yukie Tsubokura, Hideaki Yoshimura, and Atsushi Satake designed the research and analyzed the data. Tomoki Ito and Shosaku Nomura supervised the laboratory studies. Atsushi Satake supervised the research and wrote the manuscript.

ACKNOWLEDGMENTS
We thank Mihoko Inoue and Ayako Kamada for their practical assistance. This work was supported by grants from Kansai Medical University and the Japanese Society for the Promotion of Science (KAKENHI; grant no. 19K17874).

CONFLICT OF INTEREST
The authors declare no conflict of interest.
DATA AVAILABILITY STATEMENT
The original data for this study are available from the corresponding author on reasonable request.

ETHICS STATEMENT
This study was performed in compliance with the protocol reviewed by the Animal Care Committee and was approved by the President of the Kansai Medical University (approval number: 19-101). The experiments were conducted according to the Rules and Regulations for Animal Experimentation prescribed by the Kansai Medical University.

ORCID
Atsushi Satake http://orcid.org/0000-0002-6007-6264
Tomoki Ito http://orcid.org/0000-0001-5419-9156

REFERENCES
1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. *Lancet*. 2009;373(9674):1550-1561. doi:10.1016/S0140-6736(09)60237-3
2. Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2012;18(8):1150-1163. doi:10.1016/j.bbmt.2012.04.005
3. Murata M, Nakasone H, Kanda J, et al. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy; an analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2013;19(8):1183-1189. doi:10.1016/j.bbmt.2013.05.003
4. MacMillan ML, DeFor TE, Weisford DJ. The best endpoint for acute GVHD treatment trials. *Blood*. 2010;115(26):5412-5417. doi:10.1182/blood-2009-12-258442
5. Westin JR, Saliba RM, De Lima M, et al. Steroid-refractory acute GVHD: predictors and outcomes. *Adv Hematol*. 2011;2011:601953. doi:10.1155/2011/601953
6. Fuji S, Inoue Y, Utsunomiya A, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. *J Clin Oncol*. 2016;34(28):3426-3433. doi:10.1200/JCO.2016.67.8250
7. Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). *J Clin Oncol*. 2020;38(26):2993-3002. doi:10.1200/JCO.2019.03345
8. Xuan L, Wang Y, Huang F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. *Lancet Oncol*. 2020;21(9):1201-1212. doi:10.1016/S1470-2045(20)30455-1
9. Mathew NR, Baumgartner F, Braun L, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. *Nat Med*. 2018;24(3):282-291. doi:10.1038/nm.4484
10. Attal M, Lauwers-Cancès V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. *N Engl J Med*. 2012;366(19):1782-1791. doi:10.1056/NEJMoai1114138
11. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. *N Engl J Med*. 2012;366(19):1770-1781. doi:10.1056/NEJMoai1114083
12. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. *N Engl J Med*. 2012;366(19):1759-1769. doi:10.1056/NEJMoai1112704
13. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. *N Engl J Med*. 2007;357(21):2133-2142. doi:10.1056/NEJMoa070596
14. Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRXL4/CRBN). *Br J Haematol*. 2014;164(6):811-821. doi:10.1111/bjh.12708
15. Haslott PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. *J Exp Med*. 1998;187(11):1885-1892. doi:10.1084/jem.187.11.1885
16. Krönke J, Udesdi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. *Science*. 2014;343(6168):301-305. doi:10.1126/science.1244851
17. Lindner S, Kronke J. The molecular mechanism of thalidomide analogs in hematologic malignancies. *J Mol Med*. 2016;94(12):1327-1334. doi:10.1007/s00109-016-1450-z
18. Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. *Blood*. 2006;108(2):618-621. doi:10.1182/blood-2005-10-4184
19. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. *Blood*. 2001;98(1):210-216. doi:10.1182/blood.v98.1.210
20. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. *J Exp Med*. 1991;173(3):699-703. doi:10.1084/jem.173.3.699
21. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDs) in multiple myeloma. *Leukemia*. 2010;24(1):22-32. doi:10.1038/leu.2009.236
22. Muthu Raja KR, Kvarova L, Hajek R. Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. *Leuk Lymphoma*. 2012;53(7):1406-1408. doi:10.3109/10428194.2011.652106
23. Fostier K, Caers J, Meuleman N, et al. Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation. *Oncotarget*. 2018;9(29):20476-20489. doi:10.18632/oncotarget.24944
24. De Keersmaecker B, Fostier K, Corthals J, et al. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation. *Cancer Immunol Immunother.* 2014;63(10):1023-1036. doi:10.1007/s00262-014-1571-6

25. Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. *Cancer Immunol Immunother.* 2009;58(7):1033-1045. doi:10.1007/s00262-008-0620-4

26. Paiva B, Mateos MV, Sanchez-Abarca LI, et al. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. *Blood.* 2016;127(9):1151-1162. doi:10.1182/blood-2015-10-662320

27. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. *Blood.* 1996;88(6):3230-3239. doi:10.1182/blood.888.3230.bloodjournal8883230

28. Almeida AR, Zaragoza B, Freitas AA. Indexation as a novel mechanism of lymphocyte homeostasis: the number of CD4+CD25+ regulatory T cells is indexed to the number of IL-2-producing cells. *J Immunol.* 2006;177(1):192-200. doi:10.4049/jimmunol.177.1.192

29. Henden AS, Hill GR. Cytokines in graft-versus-host disease. *J Immunol.* 2015;194(10):4604-4612. doi:10.4049/jimmunol.1500117

30. Murai M, Yoneyama H, Ezaki T, et al. Peyer’s patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. *Nat Immunol.* 2003;4(2):154-160. doi:10.1038/ni879

31. Chen YB, McDonough S, Chen H, et al. Expression of α4β7 integrin on memory CD8(+T) cells at the presentation of acute intestinal GVHD. *Bone Marrow Transplant.* 2013;48(4):598-603. doi:10.1038/bmt.2012.191

32. Dutt S, Ermann J, Tseng D, et al. β-Selectin and beta7 integrin on donor CD4 T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease. *Blood.* 2005;106(12):4009-4015. doi:10.1182/blood-2005-06-2339

33. Petrovic A, Alpdogan O, Willis LM, et al. LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. *Blood* 2004;103(4):1542-1547. doi:10.1182/blood-2003-03-09957

34. Koyama M, Hill GR. The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease. *Blood.* 2019;134(24):2139-2148. doi:10.1182/blood.2019008823

35. Danylesko I, Bukauskas A, Paulson M, et al. Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease. *Bone Marrow Transplant.* 2019;54(7):987-993. doi:10.1038/s41409-018-0364-5

36. Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. *Nat Immunol.* 2000;1(3):199-205. doi:10.1038/79734

37. Henry JY, Labarthe MC, Meyer B, Dasgupta P, Dalglish AG, Galustian C. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs™ immunomodulatory compounds lenalidomide and pomalidomide. *ImmunoLOGY.* 2013;13(3):377-385. doi:10.1111/imm.12087

38. Reddy N, Hernandez-Illuzituri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. *Br J Haematol.* 2008;140(1):36-45. doi:10.1111/j.1365-2141.2007.06841.x

39. Phan V, Ito T, Inaba M, et al. Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses. *Blood Adv.* 2020;4(15):3572-3585. doi:10.1182/bloodadvances.2019001410

40. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. *Annu Rev Immunol.* 2012;30:531-564. doi:10.1146/annurev.immunol.25.022106.141623

41. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. *Cell.* 2008;133(5):775-787. doi:10.1016/j.cell.2008.05.009

42. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. *Nat Med.* 2003;9(9):1144-1150. doi:10.1038/nm915

43. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+CD25(+)) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. *J Exp Med.* 2002;196(3):389-399. doi:10.1084/jem.20020399

44. Joffre O, Santoloria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. *Nat Med.* 2008;14(1):88-92. doi:10.1038/nm1688

45. Bhandoola A, Tai X, Eckhaus M, et al. Peripheral expression of self-MHC-II influences the reactivity and self-tolerance of mature CD4(+) T cells: evidence from a lymphopenic T cell model. *Immunity.* 2002;17(4):425-436. doi:10.1016/s1074-1616(02)00417-x

46. Yi T, Chen Y, Wang L, et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. *Blood.* 2009;114(14):3101-3112. doi:10.1182/blood-2009-05-219402

47. LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. *Blood.* 2004;103(5):1787-1790. doi:10.1182/blood-2003-02-0361

48. Harada T, Ozaki S, Oda A, et al. Association of Th1 and Th2 tumor growth, but reduces lenalidomide immunomodulatory drug compound pomalidomide in multiple myeloma patients and its basis for immunotherapy in multiple myeloma patients. *Bone Marrow Transplant.* 2013;48(8):3239. doi:10.1038/blood.2012.1150. doi:10.1111/j.1365-2141.2007.

49. Yu Y, Wang D, Liu C, et al. Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor Tbet and ROR-α. *Blood.* 2011;118(8):5011-5020. doi:10.1182/blood-2011-03-340315
Hsu AK, Quach H, Tai T, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. *Blood*. 2011;117(5):1605-1613. doi:10.1182/blood-2010-04-278432

Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. *Cancer Immunol Immunother* 2008;57(12):1849-1859. doi:10.1007/s00262-008-0512-7

Hayashi T, Hideshima T, Akiyama M, et al. Lenalidomide down regulates the production of interferon gamma and the expression of inhibitory cytotoxic receptors of human natural killer cells. *Cell Immunol*. 2010;264(2):163-170. doi:10.1016/j.cellimm.2010.06.003

Cooley S, Parham P, Miller JS. Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. *Blood*. 2018;131(10):1053-1062. doi:10.1182/blood-2017-08-752170

Bensinger WI, Green DJ, Burwick N, Becker PS. A prospective study of lenalidomide monotherapy for relapse after allo-SCT for multiple myeloma. *Bone Marrow Transplant*. 2014;49(4):492-495. doi:10.1038/bmt.2013.219

Kneppers E, van der Holt B, Kersten MJ, et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. *Blood*. 2011;118(9):2413-2419. doi:10.1182/blood-2011-04-348292

Wolschke C, Stübig T, Hegenbart U, et al. Postallograft lenalidomide induces strong NK cell-mediated antymyeloma activity and risk for T cell-mediated GvHD: results from a phase I/II dose-finding study. *Exp Hematol*. 2013;41(2):134-142. doi:10.1016/j.exphem.2012.10.004

Sockel K, Bornhaeuser M, Mischak-Weissinger E, et al. Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENA MAINT trial. *Haematologica*. 2012;97(9):e34-e35. doi:10.3324/haematol.2012.067629

Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. *Science*. 2010;327(5971):1345-1350. doi:10.1126/science.1177319

Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antmyeloma activity of lenalidomide and pomalidomide. *Blood*. 2011;118(18):4771-4779. doi:10.1182/blood-2011-05-356063

Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. *Leukemia*. 2012;26(11):2326-2335. doi:10.1038/leu.2012.119

Xin W, Xiaohua N, Peilin C, Xin C, Yiqiong S, Qihan W. Primary function analysis of human mental retardation related gene CRBN. *Mol Biol Rep*. 2008;35(2):251-256. doi:10.1007/s11033-007-9077-3

Lee J, Zhou P. DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. *Mol Cell*. 2007;26(6):775-780. doi:10.1016/j.molcel.2007.06.001

Zhu YX, Braggio E, Shi CX, et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. *Blood*. 2014;124(4):536-545. doi:10.1182/blood-2014-02-557819

Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. *Science*. 2014;343(6168):305-309. doi:10.1126/science.1244917

Ito T, Ando H, Handa H. Teratogenic effects of thalidomide: molecular mechanisms. *Cell Mol Life Sci*. 2010;67(12):2013-2037. doi:10.1007/s00018-010-0619-9

Chamberlain PP, Lopez-Girona A, Miller K, et al. Structure of the human cereblon-DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs. *Nat Struct Mol Biol*. 2014;21(9):803-809. doi:10.1038/nsmb.2874

---

**How to cite this article**: Tsubokura Y, Yoshimura H, Satake A, et al. Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft-versus-host disease by inhibiting T-cell migration to the gastrointestinal tract. *Immun Inflamm Dis*. 2022;10:e688. doi:10.1002/iid3.688